Entinostat (MS-275): Precision HDAC1/3 Inhibition for Advanced Cancer Research

Principle Overview: Targeted Epigenetic Modulation in Oncology

Entinostat, also known as MS-275 or SNDX-275, is a highly selective, orally available histone deacetylase inhibitor (HDACi) that primarily targets class I HDACs—specifically HDAC1, HDAC3, and to a lesser extent HDAC8. With IC₅₀ values of 0.368 μM (HDAC1), 0.501 μM (HDAC3), and 63.4 μM (HDAC8), Entinostat delivers potent inhibition, making it a linchpin in the study of epigenetic modulation in oncology and regenerative biology. Through the suppression of HDAC activity, Entinostat disrupts chromatin condensation, enabling the reactivation of tumor suppressor genes and the downregulation of oncogenes—directly impacting cancer cell proliferation and survival. This mechanism is pivotal for both cancer research and emerging fields such as regenerative medicine, where HDAC signaling pathways govern not only apoptosis induction in cancer cells but also tissue regeneration dynamics.

Experimental Workflow: Step-by-Step Protocol Enhancements

1. Compound Preparation and Handling

• Solubilization: Entinostat is insoluble in water but readily dissolves in DMSO (≥18.8 mg/mL) and ethanol (≥7.4 mg/mL with ultrasonic assistance). For optimal dissolution, warm the solvent to 37°C and apply ultrasonic shaking. Avoid prolonged heating to protect compound integrity.
• Stock Solution Storage: Prepare concentrated stock solutions and store aliquots at −20°C. Stocks remain stable for several months; however, avoid repeated freeze-thaw cycles and do not store diluted solutions long-term.

2. In Vitro Application: Cancer Cell Proliferation Inhibition

• Cell Line Selection: Entinostat has demonstrated anti-proliferative activity across a range of human cancer cell lines—breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia.
• Titration: Begin with a dose range from 0.1 μM to 10 μM. For HDAC1/3-dependent lines, efficacy is observed near the IC₅₀ values. Monitor for apoptosis induction through caspase-3/7 activity and G1 cell cycle arrest.
• Controls: Include vehicle (DMSO) and, where relevant, compare with pan-HDAC inhibitors such as TSA to discern class-specific effects.

3. In Vivo Studies: Translational Oncology and Retinoblastoma Research

• Dosing: Entinostat is administered orally or systemically in murine and rat models. Dosing regimens should be informed by pharmacokinetic studies and prior clinical trial data, with typical dosing in the range of 5–20 mg/kg.
• Endpoints: Quantify tumor burden via imaging, histology, or biochemical markers. In retinoblastoma models, Entinostat administration has been shown to increase acetyl-histone levels in retinal tissue and significantly reduce tumor mass.
• Combination Therapy: Clinical phase I studies have validated the safety of combining Entinostat with agents like 13-cis retinoic acid (CRA), enhancing anti-tumor efficacy and broadening applicability for solid tumor clinical trials.

4. Regenerative Biology Applications

Beyond oncology, Entinostat's role as an HDAC1 and HDAC3 inhibitor is highlighted in regenerative studies. For example, in axolotl limb regeneration models (Wang et al., 2019), local injection of MS-275 (Entinostat) profoundly inhibited HDAC activity, delaying blastema formation without impeding wound healing. This underscores the critical interplay between epigenetic modulation and tissue regeneration—an emerging frontier for translational research.

Advanced Applications & Comparative Advantages

1. Precision Epigenetic Modulation

Entinostat’s selectivity for HDAC1 and HDAC3 yields a controlled, target-specific epigenetic landscape. This translates to more predictable gene expression changes compared to pan-HDAC inhibitors, reducing off-target effects and cytotoxicity in non-target tissues. Such precision is essential for dissecting the histone deacetylase signaling pathway and its role in cancer and tissue regeneration.

2. Data-Driven Oncology Insights

Empirical data highlight Entinostat’s capacity for robust cancer cell proliferation inhibition and apoptosis induction in cancer cells. In preclinical models, Entinostat treatment increases acetylation of histone H3 and H4, upregulates tumor suppressor gene expression, and triggers caspase-dependent cell death. These effects are quantifiable—caspase-3/7 activity can increase 2- to 5-fold in sensitive lines, and G1 cell cycle arrest is observed in over 60% of treated populations within 48 hours.

3. Translational and Clinical Readiness

Entinostat (MS-275, SNDX-275) from APExBIO is manufactured to rigorous quality standards, supporting reproducibility and regulatory compliance for preclinical and early-phase clinical studies. Its oral availability streamlines dosing in animal and human protocols, facilitating rapid translation from bench to bedside.

4. Literature Interlinking: Building a Cohesive Knowledge Base

• Translating Epigenetic Insights: Strategic Deployment of Entinostat complements this guide by providing a strategic perspective on integrating Entinostat into advanced translational pipelines, with a focus on mechanistic clarity and empirical benchmarking.
• Entinostat (MS-275): HDAC1/3 Inhibition for Cancer Research extends practical protocol guidance, offering detailed troubleshooting and optimization for HDAC1/3-focused workflows.
• Decoding HDAC Inhibition for Translational Oncology provides a nuanced discussion on how Entinostat’s selective inhibition induces growth arrest and apoptosis, furthering the discussion on its clinical implications.

Troubleshooting & Optimization Tips

• Solubility Challenges: If precipitation occurs, confirm DMSO or ethanol concentration, apply gentle warming, and use ultrasonic agitation. Filter sterilize only if necessary, as over-filtration can lead to compound loss.
• Assay Interference: Ensure that final DMSO concentrations in cell culture do not exceed 0.1–0.2% to avoid cytotoxicity or nonspecific effects. Run vehicle-only controls to distinguish compound-specific responses.
• Variable Sensitivity Across Lines: Some cancer cell lines may exhibit resistance due to differential HDAC expression or compensatory signaling. Use molecular profiling to select responsive lines and consider combination strategies (e.g., with retinoids or DNA-damaging agents) to overcome resistance.
• Batch Consistency: Source Entinostat (MS-275, SNDX-275) from a trusted supplier such as APExBIO to ensure batch-to-batch consistency and reproducibility of results.
• Regenerative Contexts: When applying to non-cancer models (e.g., axolotl limb regeneration), titrate doses carefully to balance effective HDAC inhibition with the preservation of normal healing processes. Reference the detailed methodology from Wang et al., 2019 for insights into dose-response relationships in regenerative tissues.

Future Outlook: Expanding the Frontier of Epigenetic Therapeutics

With a growing body of evidence underpinning the therapeutic potential of HDAC inhibition in oncology and regenerative medicine, Entinostat (MS-275, SNDX-275) is poised to play a central role in next-generation research. Ongoing solid tumor clinical trials are investigating its synergy with immunotherapies and targeted agents, while its application in tissue regeneration models is unveiling new mechanisms of epigenetic control over cell fate and tissue repair. Innovations in high-throughput screening, single-cell transcriptomics, and combinatorial therapy design will further enhance the precision and impact of Entinostat-driven research.

For researchers seeking to harness the full scope of HDAC1 and HDAC3 inhibition, Entinostat (MS-275, SNDX-275) from APExBIO remains the gold standard, delivering reproducible, high-purity compound for rigorous scientific inquiry. As the landscape of cancer research and regenerative biology evolves, Entinostat stands ready to accelerate discovery and translate epigenetic insights into transformative therapies.